In vitro activities of norfloxacin and ciprofloxacin against Mycobacterium tuberculosis, M. avium complex, M. chelonei, M. fortuitum, and M. kansasii
about
Diagnosis and Treatment of Disease Caused by Nontuberculous MycobacteriaThe fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitroUptake and intracellular activity of sparfloxacin in human polymorphonuclear leukocytes and tissue culture cellsMICs and MBCs of Win 57273 against Mycobacterium avium and M. tuberculosisComparative antimycobacterial activities of difloxacin, temafloxacin, enoxacin, pefloxacin, reference fluoroquinolones, and a new macrolide, clarithromycinMycobacteria and the new quinolonesFirst randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutolComparative in vitro activities of ciprofloxacin and other 4-quinolones against Mycobacterium tuberculosis and Mycobacterium intracellulare.In vitro susceptibilities of Mycobacterium tuberculosis to 10 antimicrobial agentsInhibitory and bactericidal activities of levofloxacin against Mycobacterium tuberculosis in vitro and in human macrophagesAnti-Mycobacterium avium activity of quinolones: in vitro activitiesFormulation and efficacy of liposome-encapsulated antibiotics for therapy of intracellular Mycobacterium avium infectionAntibacterial efficacy against an in vivo Salmonella typhimurium infection model and pharmacokinetics of a liposomal ciprofloxacin formulationMulticenter laboratory validation of susceptibility testing of Mycobacterium tuberculosis against classical second-line and newer antimicrobial drugs by using the radiometric BACTEC 460 technique and the proportion method with solid media.Efficacy of liposome-encapsulated ciprofloxacin in a murine model of Q fever.Novel semisynthetic antibiotics from caprazamycins A-G: caprazene derivatives and their antibacterial activity.Fluoroquinolones and tuberculosis.Current status and future development of antitubercular chemotherapy.Aerosol delivery of liposome-encapsulated ciprofloxacin: aerosol characterization and efficacy against Francisella tularensis infection in mice.Activities of ciprofloxacin and ofloxacin against rapidly growing mycobacteria with demonstration of acquired resistance following single-drug therapy.Rapid in vitro metabolic screen for antileprosy compoundsDetermination of in vitro susceptibility of Mycobacterium avium complex isolates to antimycobacterial agents by various methods.Management of bacterial keratitis: beyond exorcism towards consideration of organism and host factors.Ciprofloxacin therapy of infections caused by Pseudomonas aeruginosa and other resistant bacteriaEfficacies of liposome-encapsulated streptomycin and ciprofloxacin against Mycobacterium avium-M. intracellulare complex infections in human peripheral blood monocyte/macrophages.New drugs and regimens for treatment of TB.Respiratory and allergic disease. II. Chronic obstructive airways disease and respiratory infectionsAnalysis of DNA gyrA Gene Mutation in Clinical and Environmental Ciprofloxacin-Resistant Isolates of Non-Tuberculous Mycobacteria Using Molecular Methods.Multidrug-resistant Mycobacterium tuberculosis: molecular perspectives.Mycobacterium paraffinicum causing symptomatic pulmonary infection.Is repositioning of drugs a viable alternative in the treatment of tuberculosis?Minimal inhibitory concentrations of rifabutin, ciprofloxacin, and ofloxacin against Mycobacterium tuberculosis isolated before treatment of patients in Taiwan.Environmental metabolites of fluoroquinolones: synthesis, fractionation and toxicological assessment of some biologically active metabolites of ciprofloxacin.Norfloxacin: clinical pharmacology and clinical use.Activity of ofloxacin and pefloxacin against Mycobacterium leprae in mice.Bactericidal activity and killing rate of serum in volunteers receiving ciprofloxacin alone or in combination with vancomycin.Intracellular penetration and activity of BAY Y 3118 in human polymorphonuclear leukocytes.Recognizing drug targets using evolutionary information: implications for repurposing FDA-approved drugs against Mycobacterium tuberculosis H37Rv.New macrolide antibiotics: usefulness in infections caused by mycobacteria other than Mycobacterium tuberculosis.Triggered release of ciprofloxacin from nanostructured agglomerated vesicles.
P2860
Q22241907-43E53D8D-7EAB-4435-A91E-1A3A89704EF2Q24670241-F2ADCDF5-9C6E-413A-8E16-1895643760E7Q24676018-BAD47CF2-DF95-47BA-AB52-C7BF602394F6Q28329425-31DCE95F-7CB4-47A1-B0C1-D277D1EB429FQ28341927-BA57A26E-CEEA-4814-B028-6EF7D067E1BEQ28342507-A54E31C4-8E4A-4079-9668-096903B2A6E1Q28350470-9C14C57C-A59A-4ACB-AD1E-CAFCD6509466Q28360184-2E6CE067-A6B6-4357-AF22-8F62142E5A06Q28361078-DA982AFD-FA2A-4E73-A485-E3F4CC545D8BQ28369387-12066AF9-A962-4211-A4EF-BAF652791BF1Q28378348-E69C07C1-9C53-4F85-BC05-BE1BEF60680CQ28378749-68E59037-0A23-4455-B478-AC2324A15028Q33690455-FF9F902C-1559-462E-B923-2DE3B3F863C9Q33962909-987500EA-B3EA-4C40-858A-B252A553E90BQ34057550-83E0330D-DAD4-4D11-B7B2-2A9C636157D7Q34335455-DF188B91-53FC-4873-8637-C819A47771B1Q34519143-FB3CADF7-F343-493E-B752-5DA5084D47B7Q34768541-314AA920-23AB-4032-A833-CFCA6089695FQ35136593-28FCA96B-7C11-4485-B150-412CEB614C38Q35245733-9A773859-3E35-4A60-8741-7B1886C30ED7Q35540273-E22840A6-4A49-4C1D-A790-4BB1EC50146BQ35543136-D06E1D6E-9EF4-4AB6-BF4D-E3853CF78F9BQ35590415-29B4486F-BC03-4E48-A1C3-F24EEB25C2F3Q35646362-16EDF8FE-FCB4-4DAC-AE27-B12E3433D572Q36758404-85B73AB1-9FF3-429F-B84B-DCE383C34F96Q36825354-A2B2E434-D6B7-474B-94AF-C7E61648E050Q36894089-BC926286-6507-4926-BA1D-C5A55F6B027BQ36911434-FAA25251-D1A0-4E6B-9F40-19404BFDA708Q37092384-DBC7673F-FD55-4FA4-B0A0-4898AB1D708CQ37713455-A47CD686-24DD-42D3-92AC-6C19507F6C9FQ38053000-1CC77E5B-9546-4C4C-A06B-F154DADB9600Q38295637-7E4A8EA6-0005-4E30-A900-C4EFEF581F78Q39656263-78251291-4E32-420C-972A-9282E127501EQ39681144-12F4156A-A8A1-4607-B5DE-109F23180EADQ39828094-EA517A08-001D-4DAB-848B-B3655DEFC094Q39851720-2DE69BC8-52B5-4AA2-AA9B-87D193616277Q40286706-F1FC18CF-B060-4ECC-A96A-499914F91451Q40475389-8A7B1851-6073-4F99-8DD7-488E32473C06Q40588136-FE8630D2-71A8-4722-8D92-518AB518AF51Q41984283-FFE44750-A7AA-4079-B06D-759DE0F67E62
P2860
In vitro activities of norfloxacin and ciprofloxacin against Mycobacterium tuberculosis, M. avium complex, M. chelonei, M. fortuitum, and M. kansasii
description
1984 nî lūn-bûn
@nan
1984 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1984 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1984年の論文
@ja
1984年論文
@yue
1984年論文
@zh-hant
1984年論文
@zh-hk
1984年論文
@zh-mo
1984年論文
@zh-tw
1984年论文
@wuu
name
In vitro activities of norflox ...... M. fortuitum, and M. kansasii
@ast
In vitro activities of norflox ...... M. fortuitum, and M. kansasii
@en
In vitro activities of norflox ...... M. fortuitum, and M. kansasii
@nl
type
label
In vitro activities of norflox ...... M. fortuitum, and M. kansasii
@ast
In vitro activities of norflox ...... M. fortuitum, and M. kansasii
@en
In vitro activities of norflox ...... M. fortuitum, and M. kansasii
@nl
prefLabel
In vitro activities of norflox ...... M. fortuitum, and M. kansasii
@ast
In vitro activities of norflox ...... M. fortuitum, and M. kansasii
@en
In vitro activities of norflox ...... M. fortuitum, and M. kansasii
@nl
P2093
P2860
P356
P1476
In vitro activities of norflox ...... M. fortuitum, and M. kansasii
@en
P2093
P2860
P356
10.1128/AAC.26.1.94
P407
P577
1984-07-01T00:00:00Z